• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Friday, March 24, 2023
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

Coromandel International: ‘Buy’ with TP of Rs 1,030

by The Outlooker Web Desk
April 11, 2021
in Business
0
Coromandel International: ‘Buy’ with TP of Rs 1,030
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

CRIN’s overall fertilizer volumes grew 11% YoY in FY21 on the back of 35%/20%/16% volume growth in urea/MOP/SSP.

In this note, we have analysed volume growth for Coromandel International (CRIN) and the fertiliser industry in FY21. Moreover, we have looked at the market share trend, there lease of subsidies, price hikes for DAP/NPKS, & volume performance in 4QFY21. Here are the key insights.

Overall fertilizer industry volumes grew 8% YoY in FY21 on the back of 19% volume growth in MOP; NPKS and SSP volumes grew 17% each for FY21. Urea, which accounted for 53% of the fertiliser industry’s volumes, was up by 5% YoY in FY21. CRIN’s overall fertilizer volumes grew 11% YoY in FY21 on the back of 35%/20%/16% volume growth in urea/MOP/SSP. NPKS volumes were up 8%, while DAP volumes came in flat. CRIN leads the market in the NPKS Fertiliser segment and commands market share of 23.1% (FY21). For CRIN, NPKS formed 58% of overall volumes in FY21 – NPKS grew 8% v/s industry sales volume growth of 17%. Thus, CRIN lost 191bp market share in FY21. The top six states, which cumulatively account for 97% of CRIN’s NPKS volumes, are Andhra Pradesh (33%), Telangana (29%), Karnataka (12%), Maharashtra (11%), West Bengal (8%), and Odisha (4%). Maharashtra – the largest consumer of NPKS in India – accounts for 23% of India’s NPKS consumption. NPKS industry volumes in Maharashtra were up 35%, whereas CRIN’s sales in the state were largely in-line (-2%). Thus, strong NPKS volume growth in states wherein CRIN does not have a significant presence has impacted the company’s overall market share. Additionally, the firm is likely to generate CFO of Rs 41.3b in FY21, aided by the release of subsidies by the government. Thus, the firm’s capex plan would be a key monitorable, in our view. We expect a revenue/EBITDA/PAT CAGR of 8%/10%/13% over FY21–23E. We value CRIN at 17x FY23E EPS to arrive at TP of Rs 1,030. Maintain Buy.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
AstraZeneca Vaccine Blood Clot: Very Rare

AstraZeneca Vaccine Blood Clot: Very Rare

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Johnson and Johnson Loses Key Tuberculosis Drug Patent In India
National

Johnson and Johnson Loses Key Tuberculosis Drug Patent In India

March 24, 2023
Vandalism At Indian High Commission In London Raised In UK Parliament
National

Vandalism At Indian High Commission In London Raised In UK Parliament

March 23, 2023
Rahul Gandhi Can Be Disqualified, Say Congress Sources: 10 Points
National

Rahul Gandhi Can Be Disqualified, Say Congress Sources: 10 Points

March 23, 2023
Opposition Alleges “Conspiracy” As Rahul Gandhi Convicted For Defamation
National

Opposition Alleges “Conspiracy” As Rahul Gandhi Convicted For Defamation

March 23, 2023

Connect with us

No Result
View All Result

Archives

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • Johnson and Johnson Loses Key Tuberculosis Drug Patent In India
  • Vandalism At Indian High Commission In London Raised In UK Parliament
  • Rahul Gandhi Can Be Disqualified, Say Congress Sources: 10 Points

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.